WO2006072152A2 - Suppressor of disease-associated autoreactive b iymphocytes - Google Patents

Suppressor of disease-associated autoreactive b iymphocytes Download PDF

Info

Publication number
WO2006072152A2
WO2006072152A2 PCT/BG2006/000001 BG2006000001W WO2006072152A2 WO 2006072152 A2 WO2006072152 A2 WO 2006072152A2 BG 2006000001 W BG2006000001 W BG 2006000001W WO 2006072152 A2 WO2006072152 A2 WO 2006072152A2
Authority
WO
WIPO (PCT)
Prior art keywords
immunoglobulin
disease
suppressor
affinity
suppressor according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BG2006/000001
Other languages
French (fr)
Other versions
WO2006072152A3 (en
Inventor
Tchavdar Vassilev
Andrei Tchorbanov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP06703172A priority Critical patent/EP1844075A2/en
Publication of WO2006072152A2 publication Critical patent/WO2006072152A2/en
Anticipated expiration legal-status Critical
Publication of WO2006072152A3 publication Critical patent/WO2006072152A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • the invention relates to a suppressor of disease-associated autoreactive B lymphocytes in autoimmune disorders with three different ligands incorporated into one single molecule and manifesting affinity to one activating and to two inhibiting B cell receptors.
  • autoimmune diseases develop in approximately two percent of the human population. In these pathological states, the patients' own tissues and organs are attacked by the immune system by autoantibodies or by autoreactive T lymphocytes. Serious damage or destruction of the targeted tissue results from the autoimmune attack. Depending on the number of organs targeted, autoimmune diseases are divided into two groups - systemic and organ-specific. The anti-inflammatory and immunosuppressive drugs used presently to treat them in most cases diminish or delay the injury to the targeted tissue, but do not affect the primary disease itself. Even more, such medicines have serious and even life-threatening side-effects.
  • the synthetic DWEYSVWLSN peptide is shown to mimic antigenically native (double stranded) DNA and to be bound by disease-associated anti-DNA antibodies [Putterman, C. et al. (2000), J Immunol 164,2542].
  • Patent application PCT/BG04/00010A1 describes an agent for selective suppression of disease-associated B-lymphocytes, the agent being a chimeric antibody molecule that cross-links the B cell immunoglobulin receptors with preselected anti-self specificity with the inhibitory Fc ⁇ RllB receptors.
  • This agent is active only on IgG receptor-expressing B lymphocytes.
  • WO03/030835A3 relates to a method for designing bispecific antibodies for regulating immune responses, wherein said bispecific antibodies bind to one activating and to one inhibiting receptor. As one of the possible inhibiting receptors Fc ⁇ RIIB is chosen. CD22 is not mentioned.
  • the bispecific antibodies according to the above cited document, are only active if administered with an agent that stimulates the expression of an inhibiting receptor or one activating receptor or with additional therapeutics.
  • WO9707218 describes a fusion protein that cross-links activating antigen- specific receptors with inhibiting receptors on targeted B cells.
  • this fusion protein binds only to the human Fc ⁇ RIIB (CD32) and targets only B cells with IgG, but not these with immunoglobulin M antigen receptors [Wakabayashi, C. et al. (2002), Science 298,2392].
  • the invention relates to a suppressor of disease-associated autoreactive B lymphocytes with affinity to inhibitory B-lymphocyte receptors possessing three different ligands, incorporated into one single molecule.
  • the suppressor possesses affinity to one activating receptor and to two inhibiting B cell receptors and is build of an immunoglobulin G backbone and of two synthetic components.
  • the first of the three ligands is a part of the immunoglobulin G backbone and the second and third ligands are the two synthetic components ( Figure 1).
  • the first synthetic component coupled to the immunoglobulin G backbone, is a peptide epitope with affinity to the activating immunoglobulin receptors on targeted autoreactive B cells. It is a DNA-mimotope peptide made of ten aminoacids - DWEYSVWLSN (SEQ ID NO.1), where a hexamethylene linker is added to the C-end of the peptide.
  • the second synthetic component coupled to the immunoglobulin G backbone is a synthetic peptide GGPGG (SEQ ID NO. 2) with a hexamethylene group at its C-end.
  • a STN epitope with a free terminal 2,6 sialic acid is coupled to the N-end of the peptide ( Figure 2).
  • an immunoglobulin G backbone a mouse monoclonal IgG antibody is used. It is obtained from IP 2-11-1 hybridoma cells grown in protein-free CHO medium. The immunoglobulin fraction of the synthetic medium is isolated after the end of the cultivation by ammonium sulfate precipitation and subsequent dialysis against phosphate-buffered saline pH 7.2.
  • the monoclonal IgG antibody is coupled to the modified DWEYSVWLS N and to the STN-containing peptides using 1-ethyl- 3(3'-dimethylaminopropyl) carboimidine.HCI (EDC) [Bauminger, S. et al. (1980) Methods in Enzymology. 70,151].
  • the components for the construction of the trispecific immunoglobulin molecule are prepared as follows. A 1.5 mg/ml solution of the monoclonal IgG in phosphate buffer pH 6.0, 0.3 mg/ml solution of EDC in PBS pH 6.0 and 0.2 mg/ml solutions of both peptides in dimethylphormamide/ phosphate (ratio of 1 :9) buffer are made. 7.5 ml of the mixed peptide solution is added to 3.75 ml EDC and to 10 ml of the IgG solution, the volume is brought to 150 ml with phosphate buffered saline pH 6.0. The mixture is incubated for 16 hours at +4 0 C with constant stirring.
  • This preparation contains the trispecific immunoglobulin molecules, composed of the monoclonal IgG backbone, the modified CD22- binding STN epitope and the DNA-mimicking DWEYSVWLSN peptide.
  • the protein content of chimera solution is determined spectrophotometrically at 280 nm.
  • the purity of the constructed chimera is analyzed by SDS-PAGE under non-reducing conditions.
  • the ability of the trispecific immunoglobulin molecule according to the invention to engage the CD22 and Fc ⁇ Rllb inhibitory receptors and to suppress selectively pathological DNA-specific B lymphocytes with IgM and with IgG antigen receptors is analyzed in vivo in animals that develop spontaneously an autoimmune disease, namely systemic lupus erythematosus.
  • the study showed that the trispecific immunoglobulin molecule bound the inhibitory receptors on targeted disease-associated DNA-specific B cells and suppressed the activity of the latter.
  • the healthy animals do not excrete proteins with the urine. Proteinuria levels correlate with the severity of renal involvement in lupus.
  • the administration of the trispecific immunoglobulin molecule according to the invention resulted in the suppression of the IgM and IgG anti-DNA antibody levels, of proteinuria and in the increased survival time of the animals ( Figures 3-5).
  • Figure 1 shows a schematic drawing of the trispecific immunoglobulin molecule, according to the invention.
  • the DNA-mimicking and the STN epitopes are coupled to an IgG backbone.
  • Figure 2 represents a scheme of the constructed modified STN epitope.
  • Figure 3 shows the effect of the trispecific immunoglobulin molecule according to the invention on the levels of anti-DNA antibodies in treated lupus-prone MRL/lpr mice.
  • Figure 4 shows the effect of trispecific immunoglobulin molecule, according to the invention on albuminuria levels in treated MRL/lpr mice (* p ⁇ 0.05; **p ⁇ 0.01 and ***p ⁇ 0.001 relative to controls, unpaired f-test).
  • Figure 5 proves that the administration of the trispecific immunoglobulin molecule, according to the invention increases survival in female lupus- prone MLR/lpr mice (*p ⁇ 0.05 relative to controls, unpaired f-test).
  • a decapeptide DWEYSVWLSN (SEQ ID NO. 1), that mimics antigenically DNA, was also coupled to the IgG backbone.
  • a hexamethylene group was also added to the C-end of this peptide.
  • Example 2 Construction of the chimeric immunoglobulin molecule.
  • a 1.5 mg/ml solution of the monoclonal IgG in phosphate buffer pH 6.0, 0.3 mg/ml solution of EDC in PBS pH 6.0 and 0.2 mg/ml solutions of both peptides in dimethylphormamide/ phosphate (ratio of 1 :9) buffer are made.
  • 7.5 ml of the mixed peptide solution is added to 3.75 ml EDC and to 10 ml of the IgG solution, the volume is brought to 150 ml with phosphate buffered saline pH 6.0. The mixture is incubated for 16 hours at +4 0 C with constant stirring.
  • This preparation contains the trispecific immunoglobulin molecules, composed of the monoclonal IgG backbone, the modified CD22-binding STN epitope and the DNA-mimicking DWEYSVWLSN peptide. ( Figure 1).
  • the protein content of the solution is determined spectrometrically at 280 nm.
  • the purity of the constructed chimeric antibody is determined by SDS- PAGE under non-reducing conditions.
  • Example 3 Determinantion of the effect of the administration of the chimeric antibody in autoimmune animals, in particular in lupus-prone mice.
  • the constructed trispecific immunoglobulin molecule has been administered intravenously twice weekly (20 ug/dose) to groups of ten 7- and of 18-weeks old female MRL/lpr mice. Control group have been injected with the same amount of a similar modified antibody molecule that lacked the STN epitope and another control groups have been treated with PBS alone. It is known that female mice from this strain spontaneously develop at the age of 7-9 weeks a lupus-like disease accompanied by the appearance of high levels of disease-associated anti-double stranded DNA antibodies. These levels have been significantly reduced in the group treated with the trispecific immunoglobulin molecule, according to the invention ( Figure 3).
  • the lupus glomerulonephritis results in kidney failure that is a major cause for the death of the animals.
  • the quantity of proteins in the urine a measure of the severity of kidney disease, has been determined by using a standard dry strip test (from Bayer, UK).
  • the administration of the trispecific immunoglobulin molecule according to the invention delays the increase of albuminuria that is seen in the control animals (Figure 4).
  • the treated mice survive significantly longer than the control ones ( Figure 5).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a suppressor of disease-associated autoreactive B lymphocytes with affinity to three different B-lymphocyte receptors. The suppressor is build of an immunoglobulin G backbone and of two synthetic components and is designed for use treating autoimmune disorders.

Description

Suppressor of disease-associated autoreactive B lymphocytes
Field of the invention
The invention relates to a suppressor of disease-associated autoreactive B lymphocytes in autoimmune disorders with three different ligands incorporated into one single molecule and manifesting affinity to one activating and to two inhibiting B cell receptors.
Background of the invention
It is known that autoimmune diseases develop in approximately two percent of the human population. In these pathological states, the patients' own tissues and organs are attacked by the immune system by autoantibodies or by autoreactive T lymphocytes. Serious damage or destruction of the targeted tissue results from the autoimmune attack. Depending on the number of organs targeted, autoimmune diseases are divided into two groups - systemic and organ-specific. The anti-inflammatory and immunosuppressive drugs used presently to treat them in most cases diminish or delay the injury to the targeted tissue, but do not affect the primary disease itself. Even more, such medicines have serious and even life-threatening side-effects.
Autoreactive B-lymphocytes are logical targets for a selective therapeutic intervention in antibody-mediated autoimmune diseases and the efforts for their selective suppression and/or elimination are well founded. It has been shown that the disease-associated antibodies in lupus-prone (NZBx NZW)Ψλ mice are produced by B-1 cells. The continuous elimination of these cells from the very earliest age prevents the development of glomerulonephritis and increases significantly the animal's life-span [Murakami, M. et al. (1995) Intern. Immunol. 7,877]. This therapeutic approach is, however, not effective in MRL/lpr mice and in lupus patients as their DNA-specific B-lymphocytes belong to the B-2 type. The studies of R. Furie et al. show that the selective induction of single signal anergy results in selective inactivation of disease-associated B cells. Their surface immunoglobulin receptor is engaged by an artificial molecule, containing oligovalent B cell epitopes, linked to a non-immunogenic carrier (LJP394). It suppresses in vivo DNA-specific B cells in BXSB mice developing spontaneously a lupus-like disease. The administration of this immunomodulator results in diminished kidney damage and in increased time of survival. LJP394 has already shown encouraging results in phase Il of clinical trials [Furie, R.A. et al. (2001). J Rheumatol 28,257].
It is known that the effect of the binding of the immunoglobulin receptor on B cells largely depends on the signals from stimulatory and inhibitory co- receptors on the surface of the same cell [Ravech, J. et al. (2000), Science 290, 84]. The suppressive effect of the B lymphocyte receptor CD22 on the functions of these cells is well documented. Its physiological ligand remains unknown, but it is established that it binds to oligosaccharides with a terminal 2,6 sialic acid. It has been shown that the cross-linking of CD22 and of the IgM immunoglobulin receptors results in suppression of the cell's activity [Jin, L. et al. (2002) J. Exp. Med. 195,1199, Wakabayashi, C. et al. (2002), Science 298,2392].
The synthetic DWEYSVWLSN peptide is shown to mimic antigenically native (double stranded) DNA and to be bound by disease-associated anti-DNA antibodies [Putterman, C. et al. (2000), J Immunol 164,2542].
It is also well known that when immune complexes, composed of an IgG antibody and an antigen, cross-link the FcγR for IgG, type lib (FcγRllb) and the surface immunoglobulin receptor of B lymphocytes, the activity of the latter cells is specifically suppressed [Ravech, J. et al. (2000), Science 290, 84, Nimmerjahn, F. et al. (2005) Science, 310,1510]. Patent application PCT/BG04/00010A1 describes an agent for selective suppression of disease-associated B-lymphocytes, the agent being a chimeric antibody molecule that cross-links the B cell immunoglobulin receptors with preselected anti-self specificity with the inhibitory FcγRllB receptors. This agent is active only on IgG receptor-expressing B lymphocytes. WO03/030835A3 relates to a method for designing bispecific antibodies for regulating immune responses, wherein said bispecific antibodies bind to one activating and to one inhibiting receptor. As one of the possible inhibiting receptors FcγRIIB is chosen. CD22 is not mentioned. The bispecific antibodies, according to the above cited document, are only active if administered with an agent that stimulates the expression of an inhibiting receptor or one activating receptor or with additional therapeutics.
WO9707218 describes a fusion protein that cross-links activating antigen- specific receptors with inhibiting receptors on targeted B cells. However, this fusion protein binds only to the human FcγRIIB (CD32) and targets only B cells with IgG, but not these with immunoglobulin M antigen receptors [Wakabayashi, C. et al. (2002), Science 298,2392].
Description of the invention
The invention relates to a suppressor of disease-associated autoreactive B lymphocytes with affinity to inhibitory B-lymphocyte receptors possessing three different ligands, incorporated into one single molecule. The suppressor possesses affinity to one activating receptor and to two inhibiting B cell receptors and is build of an immunoglobulin G backbone and of two synthetic components. The first of the three ligands is a part of the immunoglobulin G backbone and the second and third ligands are the two synthetic components (Figure 1).
The first synthetic component, coupled to the immunoglobulin G backbone, is a peptide epitope with affinity to the activating immunoglobulin receptors on targeted autoreactive B cells. It is a DNA-mimotope peptide made of ten aminoacids - DWEYSVWLSN (SEQ ID NO.1), where a hexamethylene linker is added to the C-end of the peptide.
The second synthetic component coupled to the immunoglobulin G backbone, is a synthetic peptide GGPGG (SEQ ID NO. 2) with a hexamethylene group at its C-end. A STN epitope with a free terminal 2,6 sialic acid is coupled to the N-end of the peptide (Figure 2). As an immunoglobulin G backbone a mouse monoclonal IgG antibody is used. It is obtained from IP 2-11-1 hybridoma cells grown in protein-free CHO medium. The immunoglobulin fraction of the synthetic medium is isolated after the end of the cultivation by ammonium sulfate precipitation and subsequent dialysis against phosphate-buffered saline pH 7.2.
After the purification stage the monoclonal IgG antibody is coupled to the modified DWEYSVWLS N and to the STN-containing peptides using 1-ethyl- 3(3'-dimethylaminopropyl) carboimidine.HCI (EDC) [Bauminger, S. et al. (1980) Methods in Enzymology. 70,151].
The components for the construction of the trispecific immunoglobulin molecule are prepared as follows. A 1.5 mg/ml solution of the monoclonal IgG in phosphate buffer pH 6.0, 0.3 mg/ml solution of EDC in PBS pH 6.0 and 0.2 mg/ml solutions of both peptides in dimethylphormamide/ phosphate (ratio of 1 :9) buffer are made. 7.5 ml of the mixed peptide solution is added to 3.75 ml EDC and to 10 ml of the IgG solution, the volume is brought to 150 ml with phosphate buffered saline pH 6.0. The mixture is incubated for 16 hours at +4 0C with constant stirring. After that it is dialyzed at +40C against 200 volumes of PBS pH 7.0 for 16 hours and concentrated to a final volume of 20 ml using ultrafiltration through a 5 kD-pore membrane (Amicon, Millipore Corp.). This preparation contains the trispecific immunoglobulin molecules, composed of the monoclonal IgG backbone, the modified CD22- binding STN epitope and the DNA-mimicking DWEYSVWLSN peptide.
The protein content of chimera solution is determined spectrophotometrically at 280 nm. The purity of the constructed chimera is analyzed by SDS-PAGE under non-reducing conditions.
The ability of the trispecific immunoglobulin molecule according to the invention to engage the CD22 and FcγRllb inhibitory receptors and to suppress selectively pathological DNA-specific B lymphocytes with IgM and with IgG antigen receptors is analyzed in vivo in animals that develop spontaneously an autoimmune disease, namely systemic lupus erythematosus. The study showed that the trispecific immunoglobulin molecule bound the inhibitory receptors on targeted disease-associated DNA-specific B cells and suppressed the activity of the latter. The healthy animals do not excrete proteins with the urine. Proteinuria levels correlate with the severity of renal involvement in lupus. The administration of the trispecific immunoglobulin molecule according to the invention resulted in the suppression of the IgM and IgG anti-DNA antibody levels, of proteinuria and in the increased survival time of the animals (Figures 3-5).
Brief description of the Figures
Figure 1 shows a schematic drawing of the trispecific immunoglobulin molecule, according to the invention. The DNA-mimicking and the STN epitopes are coupled to an IgG backbone.
Figure 2 represents a scheme of the constructed modified STN epitope.
Figure 3 shows the effect of the trispecific immunoglobulin molecule according to the invention on the levels of anti-DNA antibodies in treated lupus-prone MRL/lpr mice.
Figure 4 shows the effect of trispecific immunoglobulin molecule, according to the invention on albuminuria levels in treated MRL/lpr mice (* p<0.05; **p<0.01 and ***p<0.001 relative to controls, unpaired f-test).
Figure 5 proves that the administration of the trispecific immunoglobulin molecule, according to the invention increases survival in female lupus- prone MLR/lpr mice (*p<0.05 relative to controls, unpaired f-test).
The following Examples are set out without limiting the scope and the spirit of the invention.
Example 1. Construction of the modified peptides.
An olygosaccharide STN epitope with a free terminal sialic acid (purchased from Calbiochem, Darmstadt, Germany) was coupled to the N-end of a synthetic GGPGG peptide (SEQ ID No. 2). A hexamethylene group was added to the C-end of the same peptide. Synthesis was performed using the Fmoc method [Chan, W. et al. (2000) Fmoc Solid Phase Peptide Synthesis A Practical Approach, Oxford University Press].
A decapeptide DWEYSVWLSN (SEQ ID NO. 1), that mimics antigenically DNA, was also coupled to the IgG backbone. A hexamethylene group was also added to the C-end of this peptide.
Example 2. Construction of the chimeric immunoglobulin molecule.
Both modified peptides are purified by the HPLC technology [Mehod, A.R. et al. (2002) J. Chrom.A 972,87] and then coupled to the mouse monoclonal IgG using 1-ethyl-3(3'-dimethylaminoprpyl) carboimidine.HCI (ECL) [Bauminger, S. et al. (1980) Methods in Enzymology. 70,151]. The components for the construction of the trispecific immunoglobulin molecule are prepared as follows. A 1.5 mg/ml solution of the monoclonal IgG in phosphate buffer pH 6.0, 0.3 mg/ml solution of EDC in PBS pH 6.0 and 0.2 mg/ml solutions of both peptides in dimethylphormamide/ phosphate (ratio of 1 :9) buffer are made. 7.5 ml of the mixed peptide solution is added to 3.75 ml EDC and to 10 ml of the IgG solution, the volume is brought to 150 ml with phosphate buffered saline pH 6.0. The mixture is incubated for 16 hours at +4 0C with constant stirring. After that it is dialyzed at +40C against 200 volumes of PBS pH 7.0 for 16 hours and concentrated to a final volume of 20 ml using ultrafiltration through a 5 kD-pore membrane {Amicon, Millipore Corp.). This preparation contains the trispecific immunoglobulin molecules, composed of the monoclonal IgG backbone, the modified CD22-binding STN epitope and the DNA-mimicking DWEYSVWLSN peptide. (Figure 1).
The protein content of the solution is determined spectrometrically at 280 nm. The purity of the constructed chimeric antibody is determined by SDS- PAGE under non-reducing conditions.
Example 3. Determinantion of the effect of the administration of the chimeric antibody in autoimmune animals, in particular in lupus-prone mice. The constructed trispecific immunoglobulin molecule has been administered intravenously twice weekly (20 ug/dose) to groups of ten 7- and of 18-weeks old female MRL/lpr mice. Control group have been injected with the same amount of a similar modified antibody molecule that lacked the STN epitope and another control groups have been treated with PBS alone. It is known that female mice from this strain spontaneously develop at the age of 7-9 weeks a lupus-like disease accompanied by the appearance of high levels of disease-associated anti-double stranded DNA antibodies. These levels have been significantly reduced in the group treated with the trispecific immunoglobulin molecule, according to the invention (Figure 3).
The lupus glomerulonephritis results in kidney failure that is a major cause for the death of the animals. The quantity of proteins in the urine, a measure of the severity of kidney disease, has been determined by using a standard dry strip test (from Bayer, UK). The administration of the trispecific immunoglobulin molecule according to the invention, delays the increase of albuminuria that is seen in the control animals (Figure 4). The treated mice survive significantly longer than the control ones (Figure 5).

Claims

1. Suppressor of disease- associated autoreactive B lymphocytes with affinity to inhibitory B-lymphocyte receptors, characterized in that three different ligands are incorporated into one single molecule manifesting affinity to one activating and to two inhibiting B cell receptors.
2. Suppressor according to Claim 1 characterized in that it is constructed of an immunoglobulin G backbone and two synthetic components coupled to it.
3. Suppressor according to Claims 1 and 2 characterized in that the first of the three ligands is a part of the immunoglobulin G backbone and the second and third ligands are the two synthetic components.
4. Suppressor according to Claims 1 , 2 and 2 characterized in that the first of the synthetic components is a peptide epitope with affinity to the activating immunoglobulin receptors on targeted autoreactive B cells.
5. Suppressor according to Claims 1 and 2 characterized in that the second of the synthetic components has affinity to the inhibiting B cell receptor CD22.
6. Suppressor according to Claims 1 , 2 and 3 characterized in that the immunoglobulin G backbone has affinity to the inhibiting B cell receptor Fc gamma RIIb.
7. Suppressor according to Claims 1 , 2, 3 and 5 characterized in that the second synthetic component is composed of the peptide GGPGG (SEQ ID NO. 2) with a hexamethylene group at its C-end and a STN epitope with a free terminal 2,6 sialic acid at its N-end.
8. Use of the suppressor according to Claims 1-7 in the manufacture of a medicament for the treatment of disorders caused by disease-associated autoreactive B lymphocytes.
PCT/BG2006/000001 2005-01-05 2006-01-04 Suppressor of disease-associated autoreactive b iymphocytes Ceased WO2006072152A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06703172A EP1844075A2 (en) 2005-01-05 2006-01-04 Suppressor of disease-associated autoreactive b iymphocytes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BG109003A BG65954B1 (en) 2005-01-05 2005-01-05 Means for selective suppression of the activity of pathologic autoreactive b-cells
BG109003 2005-01-05

Publications (2)

Publication Number Publication Date
WO2006072152A2 true WO2006072152A2 (en) 2006-07-13
WO2006072152A3 WO2006072152A3 (en) 2008-12-24

Family

ID=36647833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BG2006/000001 Ceased WO2006072152A2 (en) 2005-01-05 2006-01-04 Suppressor of disease-associated autoreactive b iymphocytes

Country Status (3)

Country Link
EP (1) EP1844075A2 (en)
BG (1) BG65954B1 (en)
WO (1) WO2006072152A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184203A1 (en) 2014-05-29 2015-12-03 Macrogenics, Inc. Tri-specific binding molecules and methods of use thereof
WO2018175993A1 (en) * 2017-03-24 2018-09-27 Orpheus Bioscience Inc. Pantids for treatment of autoimmune disorders
US11174315B2 (en) 2015-10-08 2021-11-16 Macrogenics, Inc. Combination therapy for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9516760D0 (en) * 1995-08-16 1995-10-18 Sandoz Ltd Organic compounds
US6001964A (en) * 1995-09-20 1999-12-14 Albert Einstein College Of Medicine Of Yeshiva University Peptides which bind to anti-double stranded DNA antibody
US7118743B2 (en) * 1998-11-17 2006-10-10 Tanox, Inc. Bispecific molecules cross-linking ITIM and ITAM for therapy
CA2462883A1 (en) * 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
BG65715B1 (en) * 2003-09-04 2009-08-31 Чавдар ВАСИЛЕВ Device for selective suppression of pathologic dna-specific b cells

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184203A1 (en) 2014-05-29 2015-12-03 Macrogenics, Inc. Tri-specific binding molecules and methods of use thereof
US10633440B2 (en) 2014-05-29 2020-04-28 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
EP3954703A2 (en) 2014-05-29 2022-02-16 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
US11697684B2 (en) 2014-05-29 2023-07-11 Macrogenics, Inc. Tri-specific binding molecules that specifically bind to multiple cancer antigens
US11820818B2 (en) 2014-05-29 2023-11-21 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
US11174315B2 (en) 2015-10-08 2021-11-16 Macrogenics, Inc. Combination therapy for the treatment of cancer
WO2018175993A1 (en) * 2017-03-24 2018-09-27 Orpheus Bioscience Inc. Pantids for treatment of autoimmune disorders

Also Published As

Publication number Publication date
BG65954B1 (en) 2010-07-30
BG109003A (en) 2006-07-31
EP1844075A2 (en) 2007-10-17
WO2006072152A3 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
US6660266B1 (en) Reversal of proinflammatory response by ligating the macrophage FcγRI receptor
CA2146647C (en) Treatment of autoimmune and inflammatory disorders
JP6225142B2 (en) Fusion proteins of natural human protein fragments for making regularly multimerized immunoglobulin Fc compositions
Matsuda et al. Human platelets can initiate T cell-dependent contact sensitivity through local serotonin release mediated by IgE antibodies
US5958409A (en) Method for treating multiple sclerosis
Van de Loo et al. Role of interleukin 1 in antigen-induced exacerbations of murine arthritis
SK7322001A3 (en) Remedies for immunological diseases
NO320354B1 (en) Use of a CD40-binding protein which is capable of binding CD40 and prevents binding of CD40 to CD40-L in the preparation of a means for the prevention or treatment of a neoplasmic disease.
JPH05507197A (en) Soluble peptide analogs containing binding sites
JP4307743B2 (en) Immunosorbents for sepsis therapy
Giorgini et al. FcγRIII and FcγRIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies
KR19990036440A (en) Allergen-UCCD3 Fusion Protein
Tchorbanov et al. Selective silencing of DNA‐specific B lymphocytes delays lupus activity in MRL/lpr mice
CN119522234A (en) Novel CD200 fusion protein
WO2006072152A2 (en) Suppressor of disease-associated autoreactive b iymphocytes
Pugin Recognition of bacteria and bacterial products by host immune cells in sepsis
Nigrovic et al. Mast cells in autoantibody responses and arthritis
Van de Velde et al. Native soluble CD5 delivers a costimulatory signal to resting human B lymphocytes
WO1999047166A1 (en) IMMUNOMODULATORY FRAGMENTS OF POLYCLONAL ANTILYMPHOCYTE GLOBULINS (ALGs) AND USES THEREOF
CN117924430B (en) TPOR-binding peptides that promote platelet production
WO2005023871A1 (en) An agent for selective suppression disease-associated auto-reactive b-cells
Wakayama et al. IgG-mediated anaphylaxis via Fcγ receptor in CD40-deficient mice
Morris et al. Role of antigen-specific T cell help in the generation of in vivo antibody responses. I. Antigen-specific T cell help is required to generate a polyclonal IgG1 response in anti-IgD antibody-injected mice
Fridman et al. Cell-mediated effects of immunoglobulins
Dimitrova et al. Target silencing of disease-associated B-lymphocytes by chimeric molecules in SCID model of pristane-induced autoimmunity

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006703172

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006703172

Country of ref document: EP